星空体育官方入口网站网址大全-登录入口官网

A randomized phase II study comparing single-agent olaparib, single-agent cediranib, and the combinations of cediranib/olaparib, olaparib/durvalumab (MEDI4736), cediranib/durvalumab (MEDI4736), and olaparib/AZD5363 (capivasertib) in women with recurrent, persistent, or metastatic endometrial cancer

Rimel, BJ; Bender, D; Enserro, D; Westin, SN; Richardson, DL; Holman, LL; Alluri, N; Stuckey, A; Garg, R; Gill, S; Tanner, E; Leath, CA; Backes, FJ; Fleury, A; Mackay, H

JOURNAL OF CLINICAL ONCOLOGY, 2023; 41 (16):

科室
- - 订阅+
  - 更多科室
工具
服务